AR101269A1 - CANCER TREATMENT USING A CHEMICAL RECEIVER OF ANTIGEN CD33 - Google Patents
CANCER TREATMENT USING A CHEMICAL RECEIVER OF ANTIGEN CD33Info
- Publication number
- AR101269A1 AR101269A1 ARP150102311A ARP150102311A AR101269A1 AR 101269 A1 AR101269 A1 AR 101269A1 AR P150102311 A ARP150102311 A AR P150102311A AR P150102311 A ARP150102311 A AR P150102311A AR 101269 A1 AR101269 A1 AR 101269A1
- Authority
- AR
- Argentina
- Prior art keywords
- car
- heavy chain
- domain
- complementarity determining
- determining region
- Prior art date
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La solicitud proporciona composiciones y métodos para el tratamiento de enfermedades asociadas con la expresión de CD33. La solicitud se refiere también a receptor quimérico antígeno (CAR) específico para CD33, los vectores que codifican al mismo, y las células T recombinantes que comprenden el CAR CD33. La solicitud también incluye métodos de administración de una célula T modificada genéticamente que expresa un CAR que comprende un dominio de unión a CD33. Reivindicación 1: Una molécula aislada de ácido nucleico que codifica un receptor quimérico de antígeno (CAR), en donde el CAR comprende un dominio de unión a CD33 humano, un dominio de transmembrana, y un dominio de señalización intracelular y en donde dicho dominio de unión a CD33 comprende una región determinante de complementariedad de cadena pesada 1 (HC CDR1), una región una región determinante de complementariedad de cadena pesada 2 (HC CDR2) y una región determinante de complementariedad de cadena pesada 3 (HC CDR3) de cualquiera de las secuencias de aminoácidos de dominio de unión a cadena pesada CD33 enumeradas en la Tabla 2 ó 9.The application provides compositions and methods for the treatment of diseases associated with the expression of CD33. The application also refers to chimeric antigen receptor (CAR) specific for CD33, the vectors encoding it, and the recombinant T cells comprising the CD33 CAR. The application also includes methods of administration of a genetically modified T cell expressing a CAR comprising a CD33 binding domain. Claim 1: An isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the CAR comprises a human CD33 binding domain, a transmembrane domain, and an intracellular signaling domain and wherein said domain of CD33 binding comprises a heavy chain complementarity determining region 1 (HC CDR1), a region a heavy chain complementarity determining region 2 (HC CDR2) and a heavy chain complementarity determining region 3 (HC CDR3) of any of the CD33 heavy chain binding domain amino acid sequences listed in Table 2 or 9.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2014082589 | 2014-07-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR101269A1 true AR101269A1 (en) | 2016-12-07 |
Family
ID=58699641
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP150102311A AR101269A1 (en) | 2014-07-21 | 2015-07-21 | CANCER TREATMENT USING A CHEMICAL RECEIVER OF ANTIGEN CD33 |
Country Status (1)
Country | Link |
---|---|
AR (1) | AR101269A1 (en) |
-
2015
- 2015-07-21 AR ARP150102311A patent/AR101269A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR101829A1 (en) | CANCER TREATMENT USING A CLL-1 CHEMERIC ANTIGEN RECEIVER | |
CO2017000507A2 (en) | Chimeric bcma antigen receptor | |
AR125268A2 (en) | OPTIMIZATION OF ANTIBODIES THAT BIND TO THE LYMPHOCYTE ACTIVATION GENE 3 (LAG-3) AND THEIR USES | |
MX2019006340A (en) | Anti-ctla-4 antibodies and methods of use thereof. | |
JOP20210076A1 (en) | Bispecific t cell engaging antibody constructs | |
MX2023000818A (en) | Anti-ctla-4 antibodies and methods of use thereof. | |
CY1119760T1 (en) | USE OF MODIFICATION OF CELLS MODIFIED BY CHEMICAL ANTIGON CELL RECEPTORS FOR CANCER TREATMENT | |
GEP20237528B (en) | Antibodies against signal-regulatory protein alpha and methods of use | |
PH12018501554A1 (en) | Ror1 antibody compositions and related methods | |
MY195089A (en) | Anti-Tim-3 Antibodies and Methods of use thereof | |
EP4275698A3 (en) | Anti-tigit antibodies and methods of use thereof | |
MX2022005955A (en) | Methods and compositions for adoptive cell therapy. | |
MX2020001450A (en) | Methods and compositions for reducing immunosupression by tumor cells. | |
PE20171180A1 (en) | ANTI-PD-1 ANTIBODIES AND THEIR METHODS OF USE | |
MX2018005618A (en) | Chimeric receptors containing traf-inducing domains and related compositions and methods. | |
UY35468A (en) | CANCER TREATMENT USING AN ANTI-CD19 CHEMERIC ANTIGEN RECEIVER | |
AR102698A1 (en) | ANTIBODIES AGAINST CD73 AND ITS USES | |
PE20171654A1 (en) | COMPOSITIONS AND METHODS USED TO INCREASE IMMUNE RESPONSE AND IN CANCER THERAPY | |
AR101669A1 (en) | ANTIBODY CONSTRUCTS FOR CDH19 AND CD3 | |
WO2015142675A8 (en) | Treatment of cancer using chimeric antigen receptor | |
WO2015138600A3 (en) | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies | |
PE20141908A1 (en) | CD47 ANTIBODIES AND METHODS OF USE THEM | |
WO2015161267A3 (en) | Humanized and chimeric monoclonal antibodies to cd99 | |
AR109683A1 (en) | ANTIBODIES AGAINST FACTOR XI AND ITS USES | |
EA202091567A1 (en) | CHIMERIC PROTEINS MIT |